Lakefront Biotherapeutics (LKFT) Long-Term Deferred Tax (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Long-Term Deferred Tax data on file, last reported at $190831.5 in Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $190831.5, down 87.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $190831.5 (down 87.68% YoY), and the FY2025 annual result was $226988.5, down 85.59% from the prior year.
• Long-Term Deferred Tax slipped to $190831.5 in Q1 2026 per LKFT's latest filing, from $226988.5 in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $4.5 million in Q1 2022 and troughed at $190831.5 in Q1 2026.
• A 5-year average of $1.4 million and a median of $1.3 million in 2024 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2024 and 2026: Long-Term Deferred Tax soared 33.09% in 2024, then plunged 87.68% in 2026.
• A 5-year view of Long-Term Deferred Tax shows it stood at $1.4 million in 2022, then dropped by 14.89% to $1.2 million in 2023, then soared by 33.09% to $1.6 million in 2024, then sank by 85.59% to $226988.5 in 2025, then decreased by 15.93% to $190831.5 in 2026.
• Business Quant data shows LKFT's Long-Term Deferred Tax at $190831.5 in Q1 2026, $226988.5 in Q4 2025, and $979668.2 in Q3 2025.